-
1
-
-
1442283866
-
Clinical Pharmacokinetics of Everolimus
-
DOI 10.2165/00003088-200443020-00002
-
GI Kirchner I Meier-Wiedenbach MP Manns 2004 Clinical pharmacokinetics of everolimus Clin Pharmacokinet 43 83 95 14748618 10.2165/00003088-200443020- 00002 1:CAS:528:DC%2BD2cXisFGkurY%3D (Pubitemid 38283132)
-
(2004)
Clinical Pharmacokinetics
, vol.43
, Issue.2
, pp. 83-95
-
-
Kirchner, G.I.1
Meier-Wiedenbach, I.2
Manns, M.P.3
-
2
-
-
35348917266
-
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency
-
DOI 10.1158/1078-0432.CCR-06-2837
-
CH Lu SL Wyszomierski LM Tseng MH Sun KH Lan CL Neal GB Mills GN Hortobagyi FJ Esteva D Yu 2007 Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency Clin Cancer Res 13 5883 5888 17908983 10.1158/1078-0432.CCR-06-2837 1:CAS:528:DC%2BD2sXhtFSntLvJ (Pubitemid 47583915)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.19
, pp. 5883-5888
-
-
Lu, C.-H.1
Wyszomierski, S.L.2
Tseng, L.-M.3
Sun, M.-H.4
Lan, K.-H.5
Neal, C.L.6
Mills, G.B.7
Hortobagyi, G.N.8
Esteva, F.J.9
Yu, D.10
-
3
-
-
25844507104
-
Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells
-
DOI 10.1002/ijc.21222
-
W Yue J Wang Y Li P Fan RJ Santen 2005 Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells Int J Cancer 117 746 754 15957161 10.1002/ijc.21222 1:CAS:528:DC%2BD2MXht1ShsbbN (Pubitemid 41598825)
-
(2005)
International Journal of Cancer
, vol.117
, Issue.5
, pp. 746-754
-
-
Yue, W.1
Wang, J.2
Li, Y.3
Fan, P.4
Santen, R.J.5
-
4
-
-
0036488531
-
Endocrine-responsive breast cancer and strategies for combating resistance
-
S Ali RC Coombes 2002 Endocrine-responsive breast cancer and strategies for combating resistance Nat Rev Cancer 2 101 112 10.1038/nrc721 12635173 10.1038/nrc721 (Pubitemid 37328797)
-
(2002)
Nature Reviews Cancer
, vol.2
, Issue.2
, pp. 101-112
-
-
Ali, S.1
Coombes, R.C.2
-
5
-
-
34548462552
-
Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells
-
DOI 10.1016/j.jsbmb.2007.05.008, PII S0960076007001306, Proceedings of the VIII International Aromatase Conference 'Aromastase 2006' (Baltimore, Maryland USA, 18-20 September, 2006)
-
W Yue P Fan J Wang Y Li RJ Santen 2007 Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells J Steroid Biochem Mol Biol 106 102 110 S0960-0760(07)00130-6 17616457 10.1016/j.jsbmb.2007.05.008 1:CAS:528:DC%2BD2sXhtVWitb3K (Pubitemid 47362658)
-
(2007)
Journal of Steroid Biochemistry and Molecular Biology
, vol.106
, Issue.1-5
, pp. 102-110
-
-
Yue, W.1
Fan, P.2
Wang, J.3
Li, Y.4
Santen, R.J.5
-
6
-
-
42049121934
-
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance
-
DOI 10.1210/er.2006-0045
-
G Arpino L Wiechmann CK Osborne R Schiff 2008 Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance Endocr Rev 29 217 233 er.2006-0045 18216219 10.1210/er.2006-0045 1:CAS:528: DC%2BD1cXltlOhsrk%3D (Pubitemid 351519691)
-
(2008)
Endocrine Reviews
, vol.29
, Issue.2
, pp. 217-233
-
-
Arpino, G.1
Wiechmann, L.2
Osborne, C.K.3
Schiff, R.4
-
7
-
-
69249137029
-
Biological determinants of endocrine resistance in breast cancer
-
nrc2713 19701242 10.1038/nrc2713 1:CAS:528:DC%2BD1MXhtVegtrzL
-
EA Musgrove RL Sutherland 2009 Biological determinants of endocrine resistance in breast cancer Nat Rev Cancer 9 631 643 nrc2713 19701242 10.1038/nrc2713 1:CAS:528:DC%2BD1MXhtVegtrzL
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 631-643
-
-
Musgrove, E.A.1
Sutherland, R.L.2
-
8
-
-
4544388665
-
The mTOR pathway in estrogen response: A potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor letrozole in breast carcinomas (abstract)
-
J Rudloff S Zumstein-Mecker DB Evans T O'Reilly HA Lane 2004 The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor letrozole in breast carcinomas (abstract) Proc Am Assoc Cancer Res 45 A5619
-
(2004)
Proc Am Assoc Cancer Res
, vol.45
, pp. 5619
-
-
Rudloff, J.1
Zumstein-Mecker, S.2
Evans, D.B.3
O'Reilly, T.4
Lane, H.A.5
-
9
-
-
22344446415
-
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer
-
DOI 10.1158/1078-0432.CCR-04-2402
-
A Boulay J Rudloff J Ye S Zumstein-Mecker T O'Reilly DB Evans S Chen HA Lane 2005 Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer Clin Cancer Res 11 5319 5328 16033851 10.1158/1078-0432.CCR-04-2402 1:CAS:528:DC%2BD2MXmt12qu70%3D (Pubitemid 41003721)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.14
, pp. 5319-5328
-
-
Boulay, A.1
Rudloff, J.2
Ye, J.3
Zumstein-Mecker, S.4
O'Reilly, T.5
Evans, D.B.6
Chen, S.7
Lane, H.A.8
-
10
-
-
33745903146
-
Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells
-
DOI 10.1016/j.ygyno.2005.12.019, PII S0090825805011212
-
O Treeck B Wackwitz U Haus O Ortmann 2006 Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells Gynecol Oncol 102 292 299 16443261 10.1016/j.ygyno.2005.12. 019 1:CAS:528:DC%2BD28XntVSlt70%3D (Pubitemid 44041641)
-
(2006)
Gynecologic Oncology
, vol.102
, Issue.2
, pp. 292-299
-
-
Treeck, O.1
Wackwitz, B.2
Haus, U.3
Ortmann, O.4
-
11
-
-
66849136781
-
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
-
19380449 10.1200/JCO.2008.18.8391 1:CAS:528:DC%2BD1MXnslWit7s%3D
-
J Baselga V Semiglazov P van Dam A Manikhas M Bellet J Mayordomo M Campone E Kubista R Greil G Bianchi J Steinseifer B Molloy E Tokaji H Gardner P Phillips M Stumm HA Lane JM Dixon W Jonat HS Rugo 2009 Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2630 2637 19380449 10.1200/JCO.2008.18.8391 1:CAS:528:DC%2BD1MXnslWit7s%3D
-
(2009)
J Clin Oncol
, vol.27
, pp. 2630-2637
-
-
Baselga, J.1
Semiglazov, V.2
Van Dam, P.3
Manikhas, A.4
Bellet, M.5
Mayordomo, J.6
Campone, M.7
Kubista, E.8
Greil, R.9
Bianchi, G.10
Steinseifer, J.11
Molloy, B.12
Tokaji, E.13
Gardner, H.14
Phillips, P.15
Stumm, M.16
Lane, H.A.17
Dixon, J.M.18
Jonat, W.19
Rugo, H.S.20
more..
-
12
-
-
34548187212
-
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
-
DOI 10.1093/annonc/mdm170
-
M Beeram QT Tan RR Tekmal D Russell A Middleton LA De Graffenried 2007 Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling Ann Oncol 18 1323 1328 17693645 10.1093/annonc/mdm170 1:STN:280:DC%2BD2srptlyhtQ%3D%3D (Pubitemid 47305004)
-
(2007)
Annals of Oncology
, vol.18
, Issue.8
, pp. 1323-1328
-
-
Beeram, M.1
Tan, Q.-T.N.2
Tekmal, R.R.3
Russell, D.4
Middleton, A.5
DeGraffenried, L.A.6
-
13
-
-
65249190250
-
S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation
-
M807532200 19112174 10.1074/jbc.M807532200 1:CAS:528:DC%2BD1MXisVSku7s%3D
-
RL Yamnik A Digilova DC Davis ZN Brodt CJ Murphy MK Holz 2009 S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation J Biol Chem 284 6361 6369 M807532200 19112174 10.1074/jbc. M807532200 1:CAS:528:DC%2BD1MXisVSku7s%3D
-
(2009)
J Biol Chem
, vol.284
, pp. 6361-6369
-
-
Yamnik, R.L.1
Digilova, A.2
Davis, D.C.3
Brodt, Z.N.4
Murphy, C.J.5
Holz, M.K.6
-
14
-
-
73649109111
-
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163
-
JCO.2008.21.3033 19687332 10.1200/JCO.2008.21.3033 1:CAS:528: DC%2BD1MXhtlCns77K
-
SL Ellard M Clemons KA Gelmon B Norris H Kennecke S Chia K Pritchard A Eisen T Vandenberg M Taylor E Sauerbrei M Mishaeli D Huntsman W Walsh M Olivo L McIntosh L Seymour 2009 Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163 J Clin Oncol 27 4536 4541 JCO.2008.21.3033 19687332 10.1200/JCO.2008.21.3033 1:CAS:528:DC%2BD1MXhtlCns77K
-
(2009)
J Clin Oncol
, vol.27
, pp. 4536-4541
-
-
Ellard, S.L.1
Clemons, M.2
Gelmon, K.A.3
Norris, B.4
Kennecke, H.5
Chia, S.6
Pritchard, K.7
Eisen, A.8
Vandenberg, T.9
Taylor, M.10
Sauerbrei, E.11
Mishaeli, M.12
Huntsman, D.13
Walsh, W.14
Olivo, M.15
McIntosh, L.16
Seymour, L.17
-
15
-
-
52049094848
-
Down-regulation of phosphatidylinositol 3′-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer
-
18451231 10.1158/1078-0432.CCR-07-1046 1:CAS:528:DC%2BD1cXlsV2qt7g%3D
-
D Generali SB Fox MP Brizzi G Allevi S Bonardi S Aguggini M Milani A Bersiga L Campo R Dionisio F Vergoni R Giardini L Dogliotti A Bottini AL Harris A Berruti 2008 Down-regulation of phosphatidylinositol 3′-kinase/AKT/ molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer Clin Cancer Res 14 2673 2680 18451231 10.1158/1078-0432.CCR-07-1046 1:CAS:528:DC%2BD1cXlsV2qt7g%3D
-
(2008)
Clin Cancer Res
, vol.14
, pp. 2673-2680
-
-
Generali, D.1
Fox, S.B.2
Brizzi, M.P.3
Allevi, G.4
Bonardi, S.5
Aguggini, S.6
Milani, M.7
Bersiga, A.8
Campo, L.9
Dionisio, R.10
Vergoni, F.11
Giardini, R.12
Dogliotti, L.13
Bottini, A.14
Harris, A.L.15
Berruti, A.16
-
16
-
-
58249084142
-
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer
-
19064988 10.1200/JCO.2007.13.7083
-
D Generali FM Buffa A Berruti MP Brizzi L Campo S Bonardi A Bersiga G Allevi M Milani S Aguggini M Papotti L Dogliotti A Bottini AL Harris SB Fox 2009 Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer J Clin Oncol 27 227 234 19064988 10.1200/JCO.2007.13.7083
-
(2009)
J Clin Oncol
, vol.27
, pp. 227-234
-
-
Generali, D.1
Buffa, F.M.2
Berruti, A.3
Brizzi, M.P.4
Campo, L.5
Bonardi, S.6
Bersiga, A.7
Allevi, G.8
Milani, M.9
Aguggini, S.10
Papotti, M.11
Dogliotti, L.12
Bottini, A.13
Harris, A.L.14
Fox, S.B.15
-
17
-
-
33751284806
-
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
-
DOI 10.1158/0008-5472.CAN-06-1500
-
M Zakikhani R Dowling IG Fantus N Sonenberg M Pollak 2006 Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells Cancer Res 66 10269 10273 17062558 10.1158/0008-5472.CAN-06-1500 1:CAS:528:DC%2BD28XhtFGjsrvK (Pubitemid 44799743)
-
(2006)
Cancer Research
, vol.66
, Issue.21
, pp. 10269-10273
-
-
Zakikhani, M.1
Dowling, R.2
Fantus, I.G.3
Sonenberg, N.4
Pollak, M.5
-
18
-
-
0032499440
-
Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
-
DOI 10.1016/S0140-6736(97)10384-1
-
SE Hankinson WC Willett GA Colditz DJ Hunter DS Michaud B Deroo B Rosner FE Speizer M Pollak 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer Lancet 351 1393 1396 9593409 10.1016/S0140-6736(97)10384-1 1:STN:280:DyaK1c3lsVansw%3D%3D (Pubitemid 28209997)
-
(1998)
Lancet
, vol.351
, Issue.9113
, pp. 1393-1396
-
-
Hankinson, S.E.1
Willett, W.C.2
Colditz, G.A.3
Hunter, D.J.4
Michaud, D.S.5
Deroo, B.6
Rosner, B.7
Speizer, F.E.8
Pollak, M.9
-
19
-
-
32944457518
-
MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
-
DOI 10.1158/0008-5472.CAN-05-2925
-
KE O'Reilly F Rojo QB She D Solit GB Mills D Smith H Lane F Hofmann DJ Hicklin DL Ludwig J Baselga N Rosen 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 1500 1508 66/3/1500 16452206 10.1158/0008-5472.CAN-05-2925 (Pubitemid 43259931)
-
(2006)
Cancer Research
, vol.66
, Issue.3
, pp. 1500-1508
-
-
O'Reilly, K.E.1
Rojo, F.2
She, Q.-B.3
Solit, D.4
Mills, G.B.5
Smith, D.6
Lane, H.7
Hofmann, F.8
Hicklin, D.J.9
Ludwig, D.L.10
Baselga, J.11
Rosen, N.12
-
20
-
-
56949094800
-
Targeted therapies in breast cancer: Where are we now?
-
S0959-8049(08)00712-0 19013786 10.1016/j.ejca.2008.09.026 1:CAS:528:DC%2BD1cXhsVKltr%2FK
-
S Di Cosimo J Baselga 2008 Targeted therapies in breast cancer: where are we now? Eur J Cancer 44 2781 2790 S0959-8049(08)00712-0 19013786 10.1016/j.ejca.2008.09.026 1:CAS:528:DC%2BD1cXhsVKltr%2FK
-
(2008)
Eur J Cancer
, vol.44
, pp. 2781-2790
-
-
Di Cosimo, S.1
Baselga, J.2
-
21
-
-
26944498619
-
Antiestrogen-resistant human breast cancer cells require activated Protein Kinase B/Akt for growth
-
DOI 10.1677/erc.1.00946
-
T Frogne JS Jepsen SS Larsen CK Fog BL Brockdorff AE Lykkesfeldt 2005 Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth Endocr Relat Cancer 12 599 614 16172194 10.1677/erc.1.00946 1:CAS:528:DC%2BD2MXht1Sjsr3P (Pubitemid 41482995)
-
(2005)
Endocrine-Related Cancer
, vol.12
, Issue.3
, pp. 599-614
-
-
Frogne, T.1
Jepsen, J.S.2
Larsen, S.S.3
Fog, C.K.4
Brockdorff, B.L.5
Lykkesfeldt, A.E.6
-
22
-
-
33748063941
-
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
-
DOI 10.1016/j.advenzreg.2006.01.004, PII S0065257106000033, Proceedings of teh 46th International Sumposium on Regulation of the Enzym Activity ans Synthesis in Normal and Neoplastic Tissues
-
JA McCubrey LS Steelman SL Abrams JT Lee F Chang FE Bertrand PM Navolanic DM Terrian RA Franklin AB D'Assoro JL Salisbury MC Mazzarino F Stivala M Libra 2006 Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Adv Enzyme Regul 46 249 279 16854453 10.1016/j.advenzreg.2006.01.004 1:CAS:528:DC%2BD1cXhs12lurs%3D (Pubitemid 44301348)
-
(2006)
Advances in Enzyme Regulation
, vol.46
, Issue.1
, pp. 249-279
-
-
McCubrey, J.A.1
Steelman, L.S.2
Abrams, S.L.3
Lee, J.T.4
Chang, F.5
Bertrand, F.E.6
Navolanic, P.M.7
Terrian, D.M.8
Franklin, R.A.9
D'Assoro, A.B.10
Salisbury, J.L.11
Mazzarino, M.C.12
Stivala, F.13
Libra, M.14
-
23
-
-
35148885729
-
A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer
-
DOI 10.1016/j.ccr.2007.08.030, PII S1535610807002620
-
K Berns HM Horlings BT Hennessy M Madiredjo EM Hijmans K Beelen SC Linn AM Gonzalez-Angulo K Stemke-Hale M Hauptmann RL Beijersbergen GB Mills MJ van de Vijver R Bernards 2007 A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 395 402 17936563 10.1016/j.ccr.2007.08.030 1:CAS:528:DC%2BD2sXht1ais7zL (Pubitemid 47539306)
-
(2007)
Cancer Cell
, vol.12
, Issue.4
, pp. 395-402
-
-
Berns, K.1
Horlings, H.M.2
Hennessy, B.T.3
Madiredjo, M.4
Hijmans, E.M.5
Beelen, K.6
Linn, S.C.7
Gonzalez-Angulo, A.M.8
Stemke-Hale, K.9
Hauptmann, M.10
Beijersbergen, R.L.11
Mills, G.B.12
Van De Vijver, M.J.13
Bernards, R.14
-
24
-
-
0035971181
-
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance
-
11139588 10.1074/jbc.M010840200 1:CAS:528:DC%2BD3MXis1Olu7k%3D
-
RA Campbell P Bhat-Nakshatri NM Patel D Constantinidou S Ali H Nakshatri 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance J Biol Chem 276 9817 9824 11139588 10.1074/jbc.M010840200 1:CAS:528:DC%2BD3MXis1Olu7k%3D
-
(2001)
J Biol Chem
, vol.276
, pp. 9817-9824
-
-
Campbell, R.A.1
Bhat-Nakshatri, P.2
Patel, N.M.3
Constantinidou, D.4
Ali, S.5
Nakshatri, H.6
-
25
-
-
0036633164
-
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells
-
12479367 1:CAS:528:DC%2BD38XlsFSmtLk%3D
-
AS Clark K West S Streicher PA Dennis 2002 Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells Mol Cancer Ther 1 707 717 12479367 1:CAS:528: DC%2BD38XlsFSmtLk%3D
-
(2002)
Mol Cancer Ther
, vol.1
, pp. 707-717
-
-
Clark, A.S.1
West, K.2
Streicher, S.3
Dennis, P.A.4
-
26
-
-
33745241078
-
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: A mechanism of tamoxifen resistance
-
DOI 10.1158/0008-5472.CAN-05-3243
-
Y Cui I Parra M Zhang SG Hilsenbeck A Tsimelzon T Furukawa A Horii ZY Zhang RI Nicholson SA Fuqua 2006 Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance Cancer Res 66 5950 5959 16740736 10.1158/0008-5472.CAN-05-3243 1:CAS:528:DC%2BD28XltFyju74%3D (Pubitemid 43927151)
-
(2006)
Cancer Research
, vol.66
, Issue.11
, pp. 5950-5959
-
-
Cui, Y.1
Parra, I.2
Zhang, M.3
Hilsenbeck, S.G.4
Tsimelzon, A.5
Furukawa, T.6
Horii, A.7
Zhang, Z.-Y.8
Nicholson, R.I.9
Fuqua, S.A.W.10
-
27
-
-
38149081373
-
Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells
-
17942395 10.1074/jbc.M706287200 1:CAS:528:DC%2BD1cXhsFejtg%3D%3D
-
N Eckstein K Servan L Girard D Cai G von Jonquieres U Jaehde MU Kassack AF Gazdar JD Minna HD Royer 2008 Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells J Biol Chem 283 739 750 17942395 10.1074/jbc. M706287200 1:CAS:528:DC%2BD1cXhsFejtg%3D%3D
-
(2008)
J Biol Chem
, vol.283
, pp. 739-750
-
-
Eckstein, N.1
Servan, K.2
Girard, L.3
Cai, D.4
Von Jonquieres, G.5
Jaehde, U.6
Kassack, M.U.7
Gazdar, A.F.8
Minna, J.D.9
Royer, H.D.10
-
28
-
-
21744453318
-
ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis
-
DOI 10.1038/sj.onc.1208626
-
S Svensson K Jirstrom L Ryden G Roos S Emdin MC Ostrowski G Landberg 2005 ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis Oncogene 24 4370 4379 15806151 10.1038/sj.onc. 1208626 1:CAS:528:DC%2BD2MXlsVWmt74%3D (Pubitemid 40961760)
-
(2005)
Oncogene
, vol.24
, Issue.27
, pp. 4370-4379
-
-
Svensson, S.1
Jirstrom, K.2
Ryden, L.3
Roos, G.4
Emdin, S.5
Ostrowski, M.C.6
Landberg, G.7
-
29
-
-
33746832533
-
Activation of PI3K/Akt signaling and hormone resistance in breast cancer
-
16755107 10.2325/jbcs.13.137
-
E Tokunaga Y Kimura K Mashino E Oki A Kataoka S Ohno M Morita Y Kakeji H Baba Y Maehara 2006 Activation of PI3K/Akt signaling and hormone resistance in breast cancer Breast Cancer 13 137 144 16755107 10.2325/jbcs.13.137
-
(2006)
Breast Cancer
, vol.13
, pp. 137-144
-
-
Tokunaga, E.1
Kimura, Y.2
Mashino, K.3
Oki, E.4
Kataoka, A.5
Ohno, S.6
Morita, M.7
Kakeji, Y.8
Baba, H.9
Maehara, Y.10
|